Avalo Therapeutics (AVTX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.83
- Estimate
- -$0.62
- Surprise
- -33.2%
- Score today
- 4.9/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Avalo Therapeutics (AVTX) reported a wider loss than forecast — adjusted EPS of -$0.83 against the -$0.62 estimate (a 33.2% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates AVTX Sell at 4.9/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's -33.2% surprise compares with a +20.8% four-quarter average. Next scheduled report: 2027-03-04.
What argues against it
- Concentration risk — Pipeline: abdakibart (AVTX-009)
- Concentration risk — Supplier: single CDMO
- DATA_ISSUE: analyst_target_implausible (raw $34.80 vs price $7.37 — ratio 4.7×). Rejected, falling back to technical TP.
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $7.37
- Price target
- $12.92
- Stop
- $6.85
- Upside to target
- +75.3%
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
AVTX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $448.7M
- P/E (fwd)
- -3.0
- 52-week range
- $6.53–$24.27
- Off 52-week high
- 69.6%
- RSI (14)
- 56
- Volume vs avg
- 0.34×
- Score today
- 4.9/10